Advertisement

Common Bladder Management Treatments for Patients with Neurogenic Bladder

  • Jeremy B. Myers
Chapter

Abstract

Neurogenic lower urinary tract dysfunction (NLUTD) is the accepted terminology used to describe bladder symptoms and dysfunction with neurogenic bladder (NGB). The patterns of NLUTD are varied and can span benign overactive bladder resulting in simple incontinence to a high-pressure bladder causing urosepsis, hydronephrosis, and renal failure. The degree and type of NLUTD depends upon the etiology underlying NGB, the severity of the disease or injury, and where and how the nervous system is affected. In this chapter, we will summarize common medical and surgical treatments for NLUTD.

Keywords

Neurogenic bladder Management Botulinum toxin Catheter Surgery 

References

  1. 1.
    Gajewski JB, Drake MJ. Neurological lower urinary tract dysfunction essential terminology. Neurourol Urodyn. 2018;37(S6):S25–31.PubMedGoogle Scholar
  2. 2.
    Manchana T, Prasartsakulchai C. Bethanechol chloride for the prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: a randomized controlled trial study. Int J Gynecol Cancer. 2011;21(4):730–6.PubMedGoogle Scholar
  3. 3.
    Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn. 2010;29(1):112–5.PubMedGoogle Scholar
  4. 4.
    Hadiji N, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52(9):701–5.PubMedGoogle Scholar
  5. 5.
    Amarenco G, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414–21.PubMedGoogle Scholar
  6. 6.
    Kennelly MJ, et al. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009;74(4):741–5.PubMedGoogle Scholar
  7. 7.
    Krhut J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226–33.PubMedGoogle Scholar
  8. 8.
    Welk B, et al. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37(8):2810–7.PubMedGoogle Scholar
  9. 9.
    Abrams P, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–88.PubMedGoogle Scholar
  10. 10.
    Herschorn S, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75.PubMedGoogle Scholar
  11. 11.
    Cameron AP, et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062–7.PubMedGoogle Scholar
  12. 12.
    Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768–72.PubMedGoogle Scholar
  13. 13.
    Cameron AP, et al. Medical and psychosocial complications associated with method of bladder management after traumatic spinal cord injury. Arch Phys Med Rehabil. 2011;92(3):449–56.PubMedGoogle Scholar
  14. 14.
    Anderson CE, et al. Bladder emptying method is the primary determinant of urinary tract infections in patients with spinal cord injury: results from a prospective rehabilitation cohort study. BJU Int. 2019;123(2):342–52.PubMedGoogle Scholar
  15. 15.
    Husmann DA, Rathbun SR. Long-term follow up of enteric bladder augmentations: the risk for malignancy. J Pediatr Urol. 2008;4(5):381–5. discussion 386PubMedGoogle Scholar
  16. 16.
    Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol. 2011;186(5):1791–5.PubMedGoogle Scholar
  17. 17.
    Higuchi TT, et al. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010;184(6):2492–6.PubMedGoogle Scholar
  18. 18.
    Consortium for Spinal Cord M. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006;29(5):527–73.Google Scholar
  19. 19.
    Welk B, et al. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 2013;51(7):516–21.PubMedGoogle Scholar
  20. 20.
    Kreydin E, et al. Surveillance and management of urologic complications after spinal cord injury. World J Urol. 2018;36(10):1545–53.PubMedGoogle Scholar
  21. 21.
    Katsumi HK, et al. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord. 2010;48(4):325–9.PubMedGoogle Scholar
  22. 22.
    Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599–600.PubMedGoogle Scholar
  23. 23.
    Cruz F, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.PubMedGoogle Scholar
  24. 24.
    Ginsberg D, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.PubMedGoogle Scholar
  25. 25.
    Mehta S, et al. Meta-analysis of botulinum toxin a detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil. 2013;94(8):1473–81.PubMedGoogle Scholar
  26. 26.
    Del Popolo G, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–9.PubMedGoogle Scholar
  27. 27.
    Kennelly M, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36(2):368–75.PubMedGoogle Scholar
  28. 28.
    Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. J Urol. 2003;169(1):195–8.PubMedGoogle Scholar
  29. 29.
    Myers JB, et al. The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization. Neurourol Urodyn. 2019;38(1):285–94.PubMedGoogle Scholar
  30. 30.
    Redshaw JD, et al. Procedures needed to maintain functionality of adult continent catheterizable channels: a comparison of continent cutaneous ileal cecocystoplasty with tunneled catheterizable channels. J Urol. 2014;192(3):821–6.PubMedGoogle Scholar
  31. 31.
    Welk B, et al. Population based assessment of enterocystoplasty complications in adults. J Urol. 2012;188(2):464–9.PubMedGoogle Scholar
  32. 32.
    Metcalfe PD, et al. What is the need for additional bladder surgery after bladder augmentation in childhood? J Urol. 2006;176(4 Pt 2):1801–5. discussion 1805.PubMedGoogle Scholar
  33. 33.
    Rowland RG, Kropp BP. Evolution of the Indiana continent urinary reservoir. J Urol. 1994;152(6 Pt 2):2247–51.PubMedGoogle Scholar
  34. 34.
    Rowland RG, et al. Indiana continent urinary reservoir. J Urol. 1987;137(6):1136–9.PubMedGoogle Scholar
  35. 35.
    Bassett MR, et al. Urinary diversion for severe urinary adverse events of prostate radiation: results from a multi-institutional study. J Urol. 2017;197(3. Pt 1):744–50.PubMedGoogle Scholar
  36. 36.
    Myers JB, Lenherr SM. Perioperative and long-term surgical complications for the Indiana pouch and similar continent catheterizable urinary diversions. Curr Opin Urol. 2016;26(4):376–82.PubMedGoogle Scholar
  37. 37.
    Shimko MS, et al. Long-term complications of conduit urinary diversion. J Urol. 2011;185(2):562–7.PubMedGoogle Scholar
  38. 38.
    Madersbacher S, et al. Long-term outcome of ileal conduit diversion. J Urol. 2003;169(3):985–90.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Jeremy B. Myers
    • 1
    • 2
  1. 1.Genitourinary Injury and Reconstructive UrologyUniversity of Utah Department of SurgerySalt Lake CityUSA
  2. 2.University of Utah Division of UrologySalt Lake CityUSA

Personalised recommendations